Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma

Table 1

Sequential measurements of ITSS scoring and Q in the treated and control groups and P values for comparisons between different time points.

Parameter	Treated group				Control group
	Measurement	P values			Measurement	P values
		7 days	14 days	21 days		7 days	14 days	21 days
ITSS scoring [median (P25, P75)]
Baseline; (n = 5)	1 to 2	0.699	0.043	0.009	1 to 2	0.007	0.006	0.005
7 days; (n = 5)	1 to 1.5		0.051	0.008	2 to 3		0.042	0.015
14 days; (n = 5)	1 to 3			0.381	3 to 4			0.513
21 days; (n = 5)	2 to 3				3 to 4
Q (means ± SD)
Baseline; (n = 5)	0.130 to 0.307; (0.203 ± 0.065)	0.028	0.347	1.000	0.130 to 0.307; (0.203 ± 0.065)	0.076	0.016	0.016
7 days; (n = 5)	0.063 to 0.160; (0.122 ± 0.038)		0.028	0.014	0.209 to 0.374; (0.295 ± 0.059)		0.175	0.251
14 days; (n = 5)	0.130 to 0.222; (0.175 ± 0.033)			0.462	0.271 to 0.385; (0.344 ± 0.047)			0.917
21 days	0.170 to 0.207; (0.188 ± 0.017)				0.263 to 0.429; (0.349 ± 0.060)

Data were tested with Kruskal Wallis test followed by Mann–Whitney U test in case of statistical significance. There are 4 mice in the treated and 5 mice in the control group at 21 days for Q evaluation; ITSS, intratumoral susceptibility signal; SD, standard deviation.